IOBT vs. ANIX, DMAC, CLSD, ORMP, EBS, BTAI, ALLK, CLRB, ADAG, and PMVP
Should you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Anixa Biosciences (ANIX), DiaMedica Therapeutics (DMAC), Clearside Biomedical (CLSD), Oramed Pharmaceuticals (ORMP), Emergent BioSolutions (EBS), BioXcel Therapeutics (BTAI), Allakos (ALLK), Cellectar Biosciences (CLRB), Adagene (ADAG), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical preparations" industry.
Anixa Biosciences (NASDAQ:ANIX) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.
Anixa Biosciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
In the previous week, Anixa Biosciences had 6 more articles in the media than IO Biotech. MarketBeat recorded 8 mentions for Anixa Biosciences and 2 mentions for IO Biotech. Anixa Biosciences' average media sentiment score of 1.44 beat IO Biotech's score of -0.36 indicating that IO Biotech is being referred to more favorably in the news media.
29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 54.8% of IO Biotech shares are held by institutional investors. 22.6% of Anixa Biosciences shares are held by insiders. Comparatively, 2.3% of IO Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Anixa Biosciences currently has a consensus target price of $12.00, suggesting a potential upside of 300.00%. IO Biotech has a consensus target price of $8.33, suggesting a potential upside of 482.75%. Given Anixa Biosciences' higher possible upside, analysts plainly believe IO Biotech is more favorable than Anixa Biosciences.
Anixa Biosciences received 5 more outperform votes than IO Biotech when rated by MarketBeat users. However, 86.67% of users gave IO Biotech an outperform vote while only 64.29% of users gave Anixa Biosciences an outperform vote.
Anixa Biosciences has higher revenue and earnings than IO Biotech. Anixa Biosciences is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.
IO Biotech's return on equity of -44.09% beat Anixa Biosciences' return on equity.
Summary
Anixa Biosciences beats IO Biotech on 9 of the 15 factors compared between the two stocks.
Get IO Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IOBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IO Biotech Competitors List
Related Companies and Tools
